Immunogenic Factors
Showing 1 - 25 of 898
Prostate Cancer Trial in London (Nivolumab & Ipilimumab)
Active, not recruiting
- Prostate Cancer
- Nivolumab & Ipilimumab
-
London, United KingdomUniversity College London Hospital
Sep 26, 2022
Acute Limb Ischemia Trial in Russian Federation (Recombinant non-immunogenic staphylokinase (Fortelyzin®), surgical methods of
Recruiting
- Acute Limb Ischemia
- Recombinant non-immunogenic staphylokinase (Fortelyzin®)
- surgical methods of treatment
-
Kazan, Republic Of Tatarstan, Russian Federation
- +5 more
Jan 19, 2023
COVID-19 Trial in Moscow (Recombinant nonimmunogenic staphylokinase, Placebo)
Suspended
- COVID-19
- Recombinant nonimmunogenic staphylokinase
- Placebo
-
Moscow, Russian Federation
- +1 more
Oct 25, 2022
Acute Stroke Trial in Saint-Petersburg
Not yet recruiting
- Acute Stroke
-
Saint-Petersburg, Russian FederationSt. Petersburg Research Institute of Emergency Medicine named af
Jan 14, 2023
Non-celiac Gluten/Wheat Sensitivity Trial in Palermo (Urinary test)
Recruiting
- Non-celiac Gluten/Wheat Sensitivity
- Urinary test
-
Palermo, PA, Italy
- +1 more
Feb 4, 2022
Solid Tumor Trial (Hyperthermia, Radiotherapy)
Not yet recruiting
- Solid Tumor
- Hyperthermia
- Radiotherapy
- (no location specified)
Mar 7, 2022
Glioblastoma Multiforme Trial (Atezolizumab + FSRT radiation)
Not yet recruiting
- Glioblastoma Multiforme
- Atezolizumab + FSRT radiation
- (no location specified)
Jun 14, 2022
Advanced Cancer, Cervical Cancer, Triple Negative Breast Cancer Trial in Sutton (ASTX660, Pembrolizumab)
Recruiting
- Advanced Cancer
- +2 more
-
Sutton, United KingdomRoyal Marden NHS Foundation Trust
May 25, 2022
Massive Pulmonary Embolism Trial in Russian Federation (Recombinant nonimmunogenic staphylokinase, Alteplase)
Recruiting
- Massive Pulmonary Embolism
- Recombinant nonimmunogenic staphylokinase
- Alteplase
-
Barnaul, Russian Federation
- +16 more
Feb 7, 2022
Celiac Disease Trial in Ancona (Gluten (behaviour), Placebo (behaviour))
Completed
- Celiac Disease
- Gluten (behaviour)
- Placebo (behaviour)
-
Ancona, ItalyUniversity Department of Pediatrics
Mar 29, 2021
Advanced NSCLC Trial in La Jolla (Nivolumab, Oxaliplatin, Ipilimumab)
Recruiting
- Advanced NSCLC
- Nivolumab
- +2 more
-
La Jolla, CaliforniaUC San Diego Moores Cancer Center
Apr 1, 2021
Gluten Free Diet in Children and Detection of Gluten in Faecal
Completed
- Celiac Disease in Children
- detecting Gluten peptides in faecal and urine samples
-
Petach Tikva, IsraelSchneider Children's Medical Center of Israel
Sep 30, 2021
Celiac Disease, Treatment Adherence, Adolescent Trial in Seville (GlutenDetect home urine test)
Recruiting
- Celiac Disease
- +2 more
- GlutenDetect home urine test
-
Seville, SpainGrupo IHP
Nov 9, 2021
From COVID-19 Convalescents Previously Hospitalized to Identify
Completed
- Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection
- Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types
-
New Orleans, Louisiana
- +1 more
Apr 12, 2021
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in San Francisco
Active, not recruiting
- Castration Levels of Testosterone
- +6 more
- Lutetium Lu 177-PSMA-617
- Pembrolizumab
-
San Francisco, CaliforniaUniversity of California, San Francisco
Apr 11, 2022
Limbal Stem-cell Deficiency Trial in Moscow (Labial mucosal epithelium grafting for corneal limbus substitution)
Enrolling by invitation
- Limbal Stem-cell Deficiency
- Labial mucosal epithelium grafting for corneal limbus substitution
-
Moscow, Russian FederationThe S. Fyodorov Eye Microsurgery Federal State Institution
Aug 9, 2021
Mitomycin C Activity in Bladder Cancer
Unknown status
- Bladder Cancer
- This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.
-
Rozzano, Milan, ItalyHumanitas reseach hospital (ICH)
Jul 4, 2020
COVID-19 Trial in Canada (mRNA-1273 SARS-CoV-2 vaccine, BNT162b2, ChAdOx1-S [recombinant])
Recruiting
- COVID-19
- mRNA-1273 SARS-CoV-2 vaccine
- +4 more
-
Edmonton, Alberta, Canada
- +7 more
Mar 7, 2022
Immunogenic Neo-epitopes for Development of Personalised
Unknown status
- The Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome Data
- Peptides
-
London, United KingdomBarts Cancer Institute
May 5, 2020
Hypomethylating Agents in Acute Myeloid Leukemia
Unknown status
- Acute Myeloid Leukemia
- Immunogenic profile
-
Brescia, BS, Italy
- +13 more
Feb 25, 2021
Cancer Trial in Zhengzhou (tumor neoantigen)
Unknown status
- Cancer
- tumor neoantigen
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Apr 13, 2020
AImmune - Artificial Intelligence Algorithm for Identification
Unknown status
- Non Small Cell Lung Cancer
- +5 more
- Collection of biopsy (FFPE), blood (PBMC) and stool
-
Gdańsk, PolandUniversity Clinical Centre in Gdansk
Aug 7, 2020
Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)
Active, not recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +5 more
- Atezolizumab
- +9 more
-
Duarte, California
- +3 more
Nov 17, 2022